Interacting Drugs |
Lidocaine (topical) vs CYP1A2 Substrates |
Security Level |
 |
Mechanism |
CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates. |
Management |
Consider therapy modification |
Lidocaine (topical) vs CYP1A2 Substrates
Post Review about Lidocaine (topical) vs CYP1A2 Substrates Click here to cancel reply.
Other Interactions of Lidocaine (topical)
Other Interactions of CYP1A2 Substrates
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.